COMMUNIQUÉS West-GlobeNewswire

OKYO Pharma Announces Director Acquires Shares
19/03/2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain [...]
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
19/03/2026
PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable [...]
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
19/03/2026
Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client
19/03/2026
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]
Notice to convene Evaxion’s Annual General Meeting
19/03/2026
COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General [...]
Passing of Genmab A/S’ Annual General Meeting
19/03/2026
Company Announcement At Genmab A/S’ Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approved Discharge was given to the Board of Directors and the Executive Management and the year’s [...]
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
19/03/2026
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYS Expected to [...]
Cylinder Health appoints Terry Boch as CEO as demand grows for digestive health solutions
19/03/2026
Health care technology executive brings more than three decades of leadership experience and a personal connection to digestive health. CHICAGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cylinder Health today announced the [...]
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
19/03/2026
Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results in hemodialysis The [...]
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
19/03/2026
Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (“TG” or “ [...]
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
19/03/2026
Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using CNSide as it enters U.S. commercialization HOUSTON, March 19, 2026 [...]
Diadia Launches AI Platform to Finally Give Women Answers to "Unexplained" Health Problems
19/03/2026
Former Google and Reddit AI scientist builds tool to decode genetic clues standard medicine dismisses as "normal" NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- For women suffering from unexplained infertility, crushing [...]
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
19/03/2026
Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aR Substantial progress made toward Phase 2b readiness for izicopan in [...]
Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
19/03/2026
Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR conference on 4 June 2026 [...]
Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
19/03/2026
ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s eClinicalMedicine London, UK, 19 March 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage [...]
Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment
19/03/2026
Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment The Group’s strategy and recent acquisitions enable upselling to higher-value markets +8% turnover growth to € [...]
SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment
19/03/2026
RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term [...]
BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair
19/03/2026
Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis imperfecta STOCKHOLM, [...]
Les résultats 2025 de Roquette illustrent la résilience d’un portefeuille élargi, dans un contexte de marché très exigeant
19/03/2026
Les résultats 2025 de Roquette illustrent la résilience d’un portefeuille élargi, dans un contexte de marché très exigeant La stratégie du Groupe et ses acquisitions récentes lui permettent de monter en gamme sur des [...]

Pages